Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | LGMN | Q99538 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245234 | 0.83 | NR1H3 (0.36) | GRM2ALDH3A1 | |
| SCHEMBL16245000 | 0.83 | PTGDR2 (0.32) | ALDH3A1NOD2NOD1LGMN | |
| SCHEMBL2318609 | 0.83 | MAPT (0.41) | LMNANOD1 | |
| SCHEMBL2315337 | 0.83 | PCSK9 (0.35) | HTR6ALDH3A1NOD2NOD1HSD11B1 | |
| SCHEMBL2318721 | 0.83 | MTOR (0.34) | ALDH3A1NOD2NOD1HSD11B1CCNC | |
| SCHEMBL2317026 | 0.81 | KDM4E (0.42) | LMNA | |
| SCHEMBL2315328 | 0.80 | EED (0.36) | EEDTHRBLMNAGRM2CACNA1H | |
| SCHEMBL2317810 | 0.80 | ALDH1A1 (0.36) | LMNATP53 | |
| SCHEMBL16245259 | 0.79 | PIK3CA (0.37) | ABL1 | |
| SCHEMBL2317292 | 0.79 | HTR6 (0.37) | EEDTP53ABL1HTR6CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | EED 3161/4885THRB 1693/4885LMNA 2396/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | EED 3161/4885THRB 1693/4885LMNA 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.